Amarin Corporation (NASDAQ: AMRN) is a biopharmaceutical company focused on the commercialization and development of therapeutics designed to improve cardiovascular health. The company’s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa®, the company’s first FDA approved product, is a highly-pure, EPA-only, omega-3 fatty acid product currently available in the United States by prescription. For more information, visit the company’s website at www.amarincorp.com.